Mirum Pharmaceuticals
MIRM
$117.07
-4.82%
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan liver diseases, with its flagship product Livmarli (maralixibat) approved for treating cholestatic pruritus in patients with Alagille syndrome. The company has established itself as a specialized player in the niche orphan drug market, leveraging its expertise in ileal bile acid transporter (IBAT) inhibition to build a portfolio that includes three approved medicines. The current investor narrative is driven by the company's transition from a development-stage entity to a commercial-stage growth story, evidenced by accelerating revenue from its approved products and the potential for label expansions into additional rare liver conditions. Recent financial results and analyst activity suggest the market is focused on Mirum's ability to scale its commercial infrastructure and achieve profitability as it capitalizes on its exclusive market positions.…
MIRM
Mirum Pharmaceuticals
$117.07
Investment Opinion: Should I buy MIRM Today?
Rating: Hold. The core thesis is that Mirum is a compelling commercial-stage growth story with impressive execution, but its valuation already reflects near-perfect future execution, limiting near-term upside and creating asymmetric downside risk.
The company's fundamentals are strong: revenue grew 49.81% YoY to $148.93M in Q4 2025, gross margin expanded to 80.97%, and free cash flow turned positive ($54.87M TTM). However, valuation metrics are stretched, with a PS of 7.61x and deeply negative earnings multiples. The implied upside from current price to analyst EPS targets is significant but hinges on achieving an average EPS of $8.75, which is several quarters away given the current loss per share of -$0.12.
The two biggest risks are growth deceleration and multiple compression. This Hold would upgrade to a Buy if the PS ratio contracts below 6x on sustained growth, or if the company reports a second consecutive quarter of GAAP profitability. It would downgrade to a Sell if quarterly revenue growth decelerates below 30% YoY or if operating losses widen sequentially. Relative to its own history, the stock is fairly valued after its de-rating from a PS of 26x, but relative to future earnings potential, it appears fully valued, requiring flawless execution to justify the price.
Sign up to view all
MIRM 12-Month Price Forecast
Mirum presents a classic growth-at-a-price dilemma. The operational story is compelling, with explosive revenue growth, expanding margins, and a clear path to profitability. However, the stock's massive 134% run and premium sales multiple (7.61x PS) leave little room for error. The stance is neutral because the risk/reward appears balanced: the base case of continued execution offers modest upside, while the bear case of a growth scare presents significant downside. The stance would upgrade to bullish on confirmation of GAAP profitability or a pullback that improves the valuation entry point. It would turn bearish on any material deceleration in the top-line growth rate.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Mirum Pharmaceuticals's 12-month outlook, with a consensus price target around $152.19 and implied upside of +30.0% versus the current price.
Average Target
$152.19
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$94 - $152
Analyst target range
Analyst coverage for Mirum appears limited, with data indicating only 4 analysts providing estimates, which suggests this is still a relatively under-followed name typical of small to mid-cap biotechs. The consensus sentiment is overwhelmingly bullish, as evidenced by a recent string of institutional ratings from firms like TD Cowen, HC Wainwright, and Morgan Stanley, all maintaining Buy or equivalent ratings such as Overweight and Outperform throughout early 2026. The target price range implied by estimated EPS and revenue forecasts is wide, with a low revenue estimate of $1.63 billion and a high of $1.80 billion, and a low EPS estimate of $8.09 against a high of $9.26, reflecting significant uncertainty around the precise trajectory of sales growth and margin expansion. This limited but positive analyst coverage, combined with high institutional conviction in recent months, signals strong professional belief in the company's commercial strategy, though the small number of analysts also implies the stock may be more susceptible to volatility from changes in coverage or shifts in individual analyst views.
Bulls vs Bears: MIRM Investment Factors
The bull case, centered on accelerating revenue growth (49.81% YoY), rapid margin expansion, and a clear path to profitability, currently holds stronger evidence given the concrete financial progress. The bear case hinges on an extreme valuation that discounts any future misstep, with negative earnings multiples and a high PS ratio. The single most important tension in the investment debate is whether Mirum's explosive revenue growth can continue long enough to grow into its premium valuation before any growth deceleration triggers a severe multiple compression. The stock's 134% one-year run suggests the market is betting heavily on the former, but the high short ratio of 5.18 indicates significant skepticism.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $148.93 million grew 49.81% YoY, accelerating from $111.59 million in Q1 2025, demonstrating successful commercial scaling of Livmarli. Sequential quarterly growth confirms strong commercial execution and market penetration in its rare disease niche.
- Rapid Path to Profitability: Net loss narrowed dramatically from -$23.79 million in Q4 2024 to -$5.73 million in Q4 2025, a 76% improvement. Gross margin expanded to 80.97%, up from 77.09% a year ago, showing pricing power and operating leverage as sales scale.
- Strong Cash Flow & Balance Sheet: The company generated $54.87 million in TTM free cash flow, enabling self-funded operations. A current ratio of 2.67 provides ample liquidity, and the debt-to-equity ratio of 1.02 is manageable for a growth-stage biotech.
- Powerful Technical Momentum: The stock is up 133.95% over the past year, significantly outperforming the SPY's 20.95% gain. It trades at 98% of its 52-week high of $119.49, supported by a 1-month gain of 18.58%, indicating strong institutional conviction.
Bearish
- Extreme Valuation on Earnings: The forward P/E ratio is deeply negative at -1340.34x, and the trailing P/E is -168.06x, reflecting a complete lack of current earnings. The EV/EBITDA of 231.78x is exceptionally high, indicating the stock is pricing in near-perfect execution years ahead.
- High Price-to-Sales Multiple: A trailing PS ratio of 7.61x, while de-rated from 26.62x, remains elevated for a commercial-stage biotech. This multiple requires sustained ~50% revenue growth to justify, leaving no margin for commercial missteps or growth deceleration.
- Profitability Not Assured: Despite narrowing losses, the company posted a net loss in the most recent quarter (-$5.73M). Return on Equity is negative at -7.42%, and the path to consistent GAAP profitability remains unproven, creating earnings risk.
- Extended Technical Position: Trading at $117.28, just shy of its 52-week high of $119.49, the stock is vulnerable to a pullback. Recent volatility, including a sharp drop from $108.62 to $92.19 in late February, shows it remains susceptible to sudden, high-magnitude corrections.
MIRM Technical Analysis
Mirum's stock is in a powerful, sustained uptrend, having appreciated 133.95% over the past year, significantly outperforming the broader market. With a current price of $117.28, the stock is trading near the top of its 52-week range, approximately 98% of the way from its low of $47.89 to its high of $119.49, indicating strong momentum but also potential overextension as it tests all-time highs. Recent momentum remains robust, with the stock up 18.58% over the past month and 32.61% over the past three months, both figures dramatically outpacing the SPY's returns of -2.17% and 15.8%, respectively, which underscores the stock's high relative strength and its decoupling from general market weakness. Key technical support is anchored at the 52-week low of $47.89, while immediate resistance is at the 52-week high of $119.49; a decisive breakout above this level could signal a continuation of the bullish trend, whereas a failure and reversal might indicate a near-term top. The stock's beta of 0.506 suggests it has been significantly less volatile than the market during this period, which is unusual for a biotech but may reflect growing institutional confidence in its commercial execution, though this low beta reading should be monitored for a potential reversion to higher volatility typical of the sector.
Beta
0.51
0.51x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$48-$125
Price range past year
Annual Return
+130.0%
Cumulative gain past year
| Period | MIRM Return | S&P 500 |
|---|---|---|
| 1m | +15.3% | -1.3% |
| 3m | +23.7% | +14.0% |
| 6m | +48.2% | +9.5% |
| 1y | +130.0% | +20.9% |
| ytd | +50.0% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MIRM Fundamental Analysis
Mirum's revenue trajectory is impressively strong, with Q4 2025 revenue reaching $148.93 million, representing a year-over-year growth rate of 49.81%. This acceleration is evident across recent quarters, as revenue has climbed sequentially from $111.59 million in Q1 2025, indicating successful commercial execution for its lead product Livmarli and other therapies. The company's path to profitability is showing clear progress, as evidenced by a significant improvement in net income from a loss of $23.79 million in Q4 2024 to a much narrower loss of $5.73 million in Q4 2025, while gross margin remains robust at 80.97%. This margin expansion, from a gross margin of 77.09% in the year-ago quarter, demonstrates pricing power and operational leverage as sales scale, moving the company closer to breakeven. Balance sheet and cash flow health are solid, with a strong current ratio of 2.67 and positive trailing twelve-month free cash flow of $54.87 million, indicating the company can fund operations internally. However, a debt-to-equity ratio of 1.02 suggests a balanced but notable use of leverage, while a negative Return on Equity of -7.42% reflects the ongoing investments required to drive growth before achieving sustainable profitability.
Quarterly Revenue
$148932000.0B
2025-12
Revenue YoY Growth
+0.49%
YoY Comparison
Gross Margin
+0.80%
Latest Quarter
Free Cash Flow
$54873000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MIRM Overvalued?
Given Mirum's negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The stock trades at a trailing PS ratio of 7.61x, which provides a baseline grounded in current commercial performance, while the lack of a meaningful forward PE (at -1340.34x) highlights the market's focus on sales growth over near-term earnings. Comparing to industry averages is challenging as specific sector multiples are not provided in the data, but a PS ratio of 7.61x for a commercial-stage biotech with ~50% YoY growth could be considered reasonable if not slightly conservative, depending on the sustainability of that growth rate and the addressable market for its rare disease portfolio. Historically, Mirum's own PS ratio has compressed significantly from elevated levels, as it traded at 26.62x sales as recently as Q4 2025; the current multiple of 7.61x represents a dramatic de-rating towards a more mature, commercial-stage valuation, suggesting the market has shifted from pricing in speculative future sales to valuing actual, delivered revenue, which may present a more stable foundation if growth continues.
PE
-168.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -173x~367x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
231.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on valuation and the transition to profitability. The company trades at a trailing PS of 7.61x and a forward PE of -1340x, meaning any stumble in its ~50% revenue growth trajectory could cause severe multiple contraction. While net losses are narrowing (-$5.73M in Q4 2025 vs. -$23.79M a year prior), profitability is not yet assured, and the negative ROE of -7.42% reflects ongoing investment needs. The debt-to-equity of 1.02, while manageable, adds fixed obligations as the company scales.
Market & Competitive Risks include valuation compression and reliance on a niche market. The stock's PS ratio of 7.61x, though down from over 26x, remains high and is vulnerable to sector-wide de-rating if investor sentiment shifts away from growth biotechs. The company's entire growth narrative depends on its lead drug Livmarli in rare liver diseases, a small market where competitive or regulatory setbacks could disproportionately impact revenue. The stock's low beta of 0.506 is unusual for a biotech and may not persist, exposing it to potential reversion to the sector's typical higher volatility.
Worst-Case Scenario involves a growth scare triggering a valuation reset. A combination of slower-than-expected prescription growth for Livmarli, coupled with a broader biotech sell-off, could lead to a rapid de-rating. The stock could realistically fall to its 52-week low of $47.89, representing a downside of approximately -59% from the current price of $117.28. This scenario would likely be catalyzed by a quarterly revenue miss, a failed label expansion, or a significant increase in operating expenses that delays profitability, leading to analyst downgrades and a flight of momentum capital.
FAQ
The primary risk is Valuation Compression (High Severity): The PS ratio of 7.61x requires sustained hyper-growth; any slowdown could trigger a sharp de-rating. Execution Risk (High): Revenue growth is heavily dependent on one drug (Livmarli) in niche markets; a stumble in commercialization would directly impact the stock. Profitability Risk (Medium): The company is not yet consistently profitable (Q4 2025 net loss -$5.73M); delays in reaching breakeven could disappoint investors. Market Risk (Medium): The stock trades at 98% of its 52-week high ($119.49), making it technically extended and vulnerable to a pullback, as seen in February's -15% drop.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $110 and $130, assuming continued strong revenue growth and progress toward profitability without major surprises. The Bull Case (30% probability) targets $140-$160, driven by faster-than-expected profitability and positive clinical catalysts. The Bear Case (15% probability) sees a drop to $65-$90 on growth deceleration or a sector-wide de-rating. The most likely outcome is the Base Case, anchored by analyst revenue consensus of ~$1.73B and the assumption that Mirum executes its commercial plan without major hiccups but takes longer to achieve sustained earnings.
MIRM's valuation is stretched on an earnings basis but arguably fair on a sales-growth basis. The forward P/E of -1340x and trailing P/E of -168x indicate the market assigns no value to current earnings, which is typical for a pre-profitability biotech. The key metric is the Price-to-Sales ratio of 7.61x. This is high compared to many mature companies but has compressed from over 26x a year ago, reflecting a shift from speculative to commercial valuation. The market is paying a premium for proven, accelerating revenue growth (49.81% YoY). It is fairly valued if growth continues but would be overvalued if growth decelerates.
MIRM is a good buy for growth investors who can tolerate high volatility and are confident in the company's ability to maintain its current ~50% revenue growth trajectory. The stock offers significant potential upside if it achieves profitability as analysts project (avg. EPS $8.75), but carries substantial risk. The current valuation at a PS of 7.61x and negative earnings leaves no margin for error. It is not a good buy for conservative investors or those seeking near-term income, as the investment thesis relies entirely on future execution. A patient investor might consider it on pullbacks to improve the risk/reward profile.
MIRM is suitable for a long-term investment horizon of 3-5 years, not short-term trading. The investment thesis is based on the company's transition to sustained profitability and capturing its full orphan drug market potential, which will take multiple quarters to unfold. The stock's low beta of 0.506 is deceptive; it has shown high volatility with a 20.55% max drawdown, making it risky for short-term traders. Long-term investors can potentially benefit from the growth story while weathering interim volatility. There is no dividend, so total return depends entirely on capital appreciation. A minimum holding period of 18-24 months is suggested to allow key commercial and profitability milestones to be reached.